Should Escitalopram Be Discontinued in This Refractory OAB Case?
Do not discontinue escitalopram based solely on urinary symptoms—there is no established causal relationship between SSRIs and overactive bladder, and emerging evidence suggests escitalopram may actually improve OAB symptoms when depression coexists. However, proceed with urodynamic evaluation and consider interstitial cystitis/bladder pain syndrome (IC/BPS) as the next diagnostic step.
Escitalopram and Urinary Symptoms: The Evidence
Urinary Retention vs. OAB Are Different Entities
The FDA labeling for escitalopram does not list urinary frequency or urgency as adverse effects 1. The rare case reports of escitalopram-associated urinary problems describe acute urinary retention in elderly men with benign prostatic hyperplasia 2, 3—not overactive bladder symptoms. These are mechanistically and clinically distinct conditions.
Emerging Evidence Suggests Potential Benefit
Contrary to concerns about SSRIs worsening bladder symptoms, a 2025 animal study demonstrated that escitalopram reversed both depression and OAB symptoms in rats with co-occurring conditions, improving bladder capacity and inter-contraction intervals more effectively than standard OAB medications (solifenacin and mirabegron) 4. While this is preclinical data, it suggests escitalopram is unlikely to be causing the refractory urgency/frequency.
Recommended Diagnostic Algorithm
Step 1: Perform Urodynamic Studies
The 2024 AUA/SUFU OAB guideline explicitly recommends urodynamics for patients who fail to respond adequately to pharmacotherapy and minimally invasive therapies (Botox) 5. This evaluation will:
- Exclude bladder outlet obstruction
- Assess detrusor contractility
- Identify other conditions explaining treatment refractoriness
Step 2: Consider IC/BPS Evaluation
Given the negative infection workup and failure of standard OAB treatments, this presentation warrants evaluation for interstitial cystitis/bladder pain syndrome 6:
Key diagnostic features to assess:
- Presence of bladder/pelvic pain or pressure (not just urgency/frequency)
- Relationship of symptoms to bladder filling
- Duration of symptoms (IC/BPS requires ≥6 weeks)
- Pain with intercourse (dyspareunia)
Cystoscopy indications: If Hunner lesions are suspected, cystoscopy should be performed as this finding changes management entirely—patients with Hunner lesions respond to specific treatments (fulguration/resection) without requiring failure of other therapies first 6.
Step 3: Measure Post-Void Residual
Ensure PVR is checked if not recently done, as elevated PVR after Botox could explain persistent symptoms and requires different management 5.
Treatment Considerations Moving Forward
If Urodynamics Are Normal
Consider IC/BPS-directed therapies rather than additional OAB treatments 6:
- Behavioral modifications (dietary triggers, pelvic floor physical therapy)
- Oral medications (amitriptyline, pentosan polysulfate—though note recent safety concerns)
- Bladder instillations
- Pain management strategies
If Detrusor Overactivity Persists
The 2024 guideline supports combination therapy approaches 5:
- Beta-3 agonist (mirabegron/vibegron) added to or replacing prior antimuscarinic
- Consider repeat Botox if initial response was partial
- Evaluate for sacral neuromodulation or percutaneous tibial nerve stimulation 5, 7
Critical Pitfalls to Avoid
Do not attribute refractory urinary symptoms to psychiatric medications without clear temporal relationship. The patient's symptoms preceded or persisted despite escitalopram, and there's no pharmacologic mechanism linking SSRIs to OAB-type symptoms.
Do not discontinue effective psychiatric treatment based on unsubstantiated concerns. Depression itself significantly impacts quality of life and has established morbidity/mortality implications 1.
Do not pursue additional empiric OAB treatments without urodynamic confirmation that detrusor overactivity is actually present—you may be treating the wrong condition 5.
The Bottom Line
Continue escitalopram at the current dose while pursuing urodynamic evaluation to guide next steps. The refractory nature of symptoms after standard OAB therapies suggests either an incorrect diagnosis (IC/BPS, neurogenic bladder, outlet obstruction) or a specific OAB phenotype requiring neuromodulation 5, 6. Escitalopram is not contributing to the problem and may provide benefit if depression and OAB coexist 4.